Trademarkia Logo

Canada

C$
POINT BIOPHARMA DESIGN
SEARCHED

on 7 Aug 2024

Last Applicant/ Owned by

POINT BIOPHARMA CORP.

22 St. Clair Ave East, Suite 1201Toronto

ONTARIO

CA

M4T2S3

Serial Number

2043695 filed on 4th Aug 2020

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

POINT BIOPHARMA DESIGN

Trademark usage description

pharmaceutical preparations for the diagnosis and treatment of cancer and tumors; pharmaceutical preparations for the diagnosis and treatment of oncol Read More

Vienna Information


27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 19

Letters overlappingLettres se chevauchant

27 . 5 . 8

Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.Lettres liées à un élément figuratif ou contenant un élément figuratif -- Note: Les lettres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet sont classées dans la division 27.3.

24 . 17 . 5

Mathematical signsSignes mathématiques

24 . 17 . 8

Infinity SymbolSigne de l'infini

Classification Information


Class [005]
PHARMACEUTICAL PREPARATIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER AND TUMORS; PHARMACEUTICAL PREPARATIONS FOR THE DIAGNOSIS AND TREATMENT OF ONCOLOGICAL DISEASES; RADIOACTIVE PHARMACEUTICAL PRODUCTS USED IN THE FIELD OF NUCLEAR MEDICINE, INTENDED FOR MEDICAL TREATMENTS AND IMAGING; DRUG DELIVERY AGENTS CONSISTING OF COMPOUNDS THAT FACILITATE DELIVERY OF A WIDE RANGE OF PHARMACEUTICALS;


Classification kind code

11

Mark Details


Serial Number

2043695

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 22
on 7th Aug 2024
Search Recorded
Submitted for opposition 20
on 7th Aug 2024
Examiner's First Report
Submitted for opposition 48
on 30th Jan 2024
Agent Changed
Submitted for opposition 287
on 19th Apr 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 4th Aug 2020
Filed
Submitted for opposition 1
on 4th Aug 2020
Created
Submitted for opposition 31
on 4th Aug 2020
Formalized